Drug intelligence / Profile preview

INM-900

Development stage: Preclinical
Lead developer: InMed Pharmaceuticals
Modality: Small Molecules
Administration: Unknown

Overview

INM-900 is a **small molecule cannabinoid analogue** being developed by InMed Pharmaceuticals for the treatment of neurodegenerative diseases[1][3][7]. Its mechanism of action is based on the neuroprotective effects of specific cannabinoid analogs, which are hypothesized to inhibit or slow disease progression and improve neuronal function. Preclinical data suggest these compounds are highly lipophilic and capable of crossing the blood-brain barrier, making them suitable for targeting neurological disorders such as Alzheimer’s disease, Parkinson’s disease, and Huntington’s disease[3][7]. The drug is noted as utilizing a novel mechanism of action within the cannabinoid analogue class[1][3].

Brand names: INM-900INM900INM 900
Other names: INM-900INM900INM 900

Targets

CNR1 (Cannabinoid receptor 1)

Beyond the preview

Go deeper on INM-900.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on INM-900.

Explore the full profile